TY - JOUR
T1 - Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis
T2 - TRACER study
AU - Paolicelli, Damiano
AU - Cocco, Eleonora
AU - Di Lecce, Valentina
AU - Direnzo, Vita
AU - Moiola, Lucia
AU - Lanzillo, Roberta
AU - Perini, Paola
AU - Malucchi, Simona
AU - Borriello, Giovanna
AU - Portaccio, Emilio
AU - Panetta, Valentina
AU - Fenu, Giuseppe
AU - Sangalli, Francesca
AU - Cacciaguerra, Laura
AU - Trojano, Maria
AU - for the TRACER Group, the TRACER Group
PY - 2016/3/13
Y1 - 2016/3/13
N2 - Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of ‘not missing doses’, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined ‘treatment adherents’. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score
AB - Objective: The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline. Methods: We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of ‘not missing doses’, through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined ‘treatment adherents’. Results: After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26–40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score
KW - Disease-modifying drugs
KW - interferon beta
KW - patient adherence
KW - real-life setting
KW - rebismart® injection device
KW - relapsing-remitting multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84961210036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961210036&partnerID=8YFLogxK
U2 - 10.1517/17425247.2016.1158161
DO - 10.1517/17425247.2016.1158161
M3 - Article
AN - SCOPUS:84961210036
SP - 1
EP - 7
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
SN - 1742-5247
ER -